KOVALTRY

Kovaltry is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) for adults, adolescents and children of all ages... Learn about KOVALTRY - a recombinant antihemophilic factor therapy approved for hemophilia A in adults and children... This website contains information based on the Summary of Product Characteristics (SPC), as approved by the European Commission on Jivi (damoctog alfa pegol), Kovaltry (octocog alfa) and Kogenate FS (octocog alfa). It is intended to provide information to an international audience. In countries outside the EU, the local Product Information applies.

Also known as: Bayer, Bayer AG

Primary location: Mountain View United States